{"product_id":"recombinant-newcastle-disease-virus-rna-directed-rna-polymerase-l-l-partial-bhp10514498","title":"Recombinant Newcastle disease virus RNA-directed RNA polymerase L (L), partial","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eRecombinant Newcastle disease virus RNA-directed RNA polymerase L (L), partial is a recombinant protein preparation derived from Newcastle disease virus (strain Chicken\/United States\/B1\/48) (NDV). It is commonly used as a defined reagent for assay development, binding studies, and analytical controls where consistent protein specifications are required.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpressed region:\u003c\/strong\u003e 1741-1960aa.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E.coli (may influence folding and post-translational modifications).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTag\/format:\u003c\/strong\u003e N-terminal 10xHis-tagged and C-terminal Myc-tagged; Liquid or Lyophilized powder.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpected size:\u003c\/strong\u003e 32.2 kDa (as provided).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Greater than 95% as determined by SDS-PAGE.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eRegion choice, expression system, and tag\/format can influence folding, post-translational modifications, and interaction behavior in downstream assays.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eRNA-directed RNA polymerase that catalyzes the transcription of viral mRNAs, their capping and polyadenylation. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N). The viral polymerase binds to the genomic RNA at the 3' leader promoter, and transcribes subsequently all viral mRNAs with a decreasing efficiency. The first gene is the most transcribed, and the last the least transcribed. The viral phosphoprotein acts as a processivity factor. Capping is concommitant with initiation of mRNA transcription. Indeed, a GDP polyribonucleotidyl transferase (PRNTase) adds the cap structure when the nascent RNA chain length has reached few nucleotides. Ribose 2'-O methylation of viral mRNA cap precedes and facilitates subsequent guanine-N-7 methylation, both activities being carried by the viral polymerase. Polyadenylation of mRNAs occur by a stuttering mechanism at a slipery stop site present at the end viral genes. After finishing transcription of a mRNA, the polymerase can resume transcription of the downstream gene. {ECO:0000250|UniProtKB:P03523}.; RNA-directed RNA polymerase that catalyzes the replication of viral genomic RNA. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N). The replicase mode is dependent on intracellular N protein concentration. In this mode, the polymerase replicates the whole viral genome without recognizing transcriptional signals, and the replicated genome is not caped or polyadenylated.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eAntigen design and domain selection to better capture neutralizing versus non-neutralizing antibody responses.\u003c\/li\u003e\n\u003cli\u003eHigh-throughput serology and antibody screening using standardized antigens and plate-based formats.\u003c\/li\u003e\n\u003cli\u003eIntegrating binding kinetics with epitope mapping to support variant-aware immunology studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eCoat plates with NDV-L antigen for ELISA antibody titration (serum\/plasma).\u003c\/li\u003e\n\u003cli\u003eScreen anti-NDV-L antibodies by indirect ELISA and immunoblot readouts.\u003c\/li\u003e\n\u003cli\u003eMap antigenic epitopes using NDV-L fragments\/domains (in vitro binding assays).\u003c\/li\u003e\n\u003cli\u003eDevelop antigen-capture assays using NDV-L as a standard (spike-in controls).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpret results in the context of the biological system, assay format, and any known domain\/isoform constraints for the target.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eAntigenic proteins may contain immunodominant regions; domain choice can affect assay readouts and cross-reactivity.\u003c\/li\u003e\n\u003cli\u003eInclude relevant negative controls (e.g., unrelated antigens) and dilution series to support interpretation of binding signals.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProtKB entry (Q9DLD3) — UniProt: https:\/\/www.uniprot.org\/uniprotkb\/Q9DLD3 - NCBI Gene search (L) — NCBI: https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=L - PubMed search — NLM: https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=NDV-L - Reactome pathway browser — Reactome: https:\/\/reactome.org\/ - InterPro protein family resource — EMBL-EBI: https:\/\/www.ebi.ac.uk\/interpro\/ --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53059260449133,"sku":"CSB-EP887622NCTb1-1MG","price":2062.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53059364290925,"sku":"CSB-EP887622NCTb1-100UG","price":480.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53059364323693,"sku":"CSB-EP887622NCTb1-20UG","price":256.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-EP887622NCTb1-SDS.jpg?v=1772280190","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-newcastle-disease-virus-rna-directed-rna-polymerase-l-l-partial-bhp10514498","provider":"BioHippo","version":"1.0","type":"link"}